title: ERK1/2 mediates PDGF-BB stimulated vascular smooth muscle cell proliferation and migration on laminin-5.
abstract: During restenosis following arterial injury, vascular smooth muscle cells (VSMCs) form a neointimal layer in arteries by changing from a differentiated, contractile phenotype to a dedifferentiated, migratory, and proliferative phenotype. Several growth factors, cytokines, and extracellular matrix components released following injury have been implicated in these phenotypic changes. We have recently detected the expression of laminin-5, an ECM protein found predominantly in epithelial tissues, in the arterial vasculature. Here we report that ln-5 expression by VSMC is upregulated by platelet-derived growth factor (PDGF-BB), epidermal growth factor, basic fibroblast growth factor, and transforming growth factor-beta1. Adhesion to ln-5 specifically enhances PDGF-BB-stimulated VSMC proliferation and migration. PD98059, a specific inhibitor of the ERK1/2 members of the Mitogen Activated Protein kinase family, increases both VSMC adhesion to ln-5 and blocks PDGF-BB-stimulated VSMC migration on ln-5. These results suggest that adhesion to ln-5 mediates a PDGF-BB-stimulated VSMC response to vascular injury via an ERK1/2 signaling pathway.
authors.affiliation: Department of Biological Sciences, University of Nevada, Las Vegas, USA.
authors.forename: K
authors.initials: K
authors.lastname: Kingsley
authors.forename: J L
authors.initials: JL
authors.lastname: Huff
authors.forename: W L
authors.initials: WL
authors.lastname: Rust
authors.forename: K
authors.initials: K
authors.lastname: Carroll
authors.forename: A M
authors.initials: AM
authors.lastname: Martinez
authors.forename: M
authors.initials: M
authors.lastname: Fitchmun
authors.forename: G E
authors.initials: GE
authors.lastname: Plopper
mesh_terms: D000818:Animals; D000077214:Becaplermin; D015153:Blotting, Western; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000378:metabolism / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D002633:Chemotaxis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016326:Extracellular Matrix Proteins / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology; D019950:Mitogen-Activated Protein Kinase 1 / Q000502:physiology; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D000097794:Kalinin
chemical_list: D000077214:Becaplermin; D015815:Cell Adhesion Molecules; D004791:Enzyme Inhibitors; D016326:Extracellular Matrix Proteins; D005419:Flavonoids; D006133:Growth Substances; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D000097794:Kalinin; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one